Medicine and Dentistry
Non Small Cell Lung Cancer
98%
Neoplasm
43%
Lung Cancer
41%
Circulating Tumor Cell
36%
Immune Checkpoint Inhibitor
22%
Epidermal Growth Factor Receptor
19%
Overall Survival
18%
Malignant Neoplasm
16%
Small Cell Lung Cancer
15%
Circulating Tumor DNA
15%
Immunotherapy
14%
Diagnosis
13%
Progression Free Survival
13%
Quality of Life
13%
Disease
12%
Nivolumab
11%
Radiation Therapy
11%
Exon
10%
Tyrosine-Kinase Inhibitor
9%
Durvalumab
9%
Epithelial Cell Adhesion Molecule
8%
Oncology
8%
Targeted Therapy
8%
Leukapheresis
8%
Writing
8%
Asthma
8%
Patient Referral
7%
Programmed Death 1 Ligand 1
7%
Hazard Ratio
7%
Adverse Event
7%
Crizotinib
7%
Cohort Analysis
7%
Randomized Controlled Trial
6%
Resistance Mutation
6%
Disease Exacerbation
6%
Next Generation Sequencing
6%
Biological Marker
6%
ALK Inhibitor
6%
Non-Small Cell Lung Cancer
6%
COVID-19
6%
Cell-Free DNA
5%
Platelet
5%
Primary Health Care
5%
Cancer Stem Cell
5%
Pooled Analysis
5%
Secondary Care
5%
Chemoimmunotherapy
5%
Osimertinib
5%
Drug Megadose
5%
Biopsy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Neoplasm
49%
Lung Cancer
43%
Epidermal Growth Factor Receptor
30%
Immune Checkpoint Inhibitor
28%
Overall Survival
27%
Chemotherapy
24%
Biological Marker
18%
Progression Free Survival
18%
Chemoradiation Therapy
16%
Durvalumab
15%
Disease
15%
Small Cell Lung Cancer
15%
Protein Tyrosine Kinase Inhibitor
15%
Circulating Tumor DNA
14%
Nivolumab
14%
Asthma
14%
Malignant Neoplasm
11%
Adverse Event
11%
Immunotherapy
9%
Disease Exacerbation
9%
Crizotinib
8%
Randomized Controlled Trial
8%
Osimertinib
8%
Erlotinib
8%
Placebo
7%
Anaplastic Lymphoma Kinase Inhibitor
6%
Methacholine
6%
Programmed Death 1 Ligand 1
6%
Afatinib
6%
Respiratory Tract Allergy
6%
Carboplatin
6%
Docetaxel
5%
Anaplastic Lymphoma Kinase
5%
Cohort Study
5%
Epithelial Cell Adhesion Molecule
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
24%
Lung Cancer
20%
Immune Checkpoint Inhibitors
18%
Circulating Tumor Cells
11%
Non-small Cell Lung Cancer Patients
11%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
10%
Overall Survival
9%
Chemoradiotherapy
9%
Netherlands
9%
Chemotherapy
8%
Nivolumab
8%
Asthmatic
8%
Hazard Ratio
7%
Tumor Response
7%
Quality of Life
7%
Asthma
7%
Confidence Interval
6%
Durvalumab
6%
Dutch
6%
Groningen
5%
Older Patients
5%
Treatment Goals
5%
Epidermal Growth Factor Receptor
5%
Prioritization Tool
5%
Advanced Lung Adenocarcinoma
5%
Genomic Scars
5%
MRNA-1273
5%
Mutational Profile
5%
Molecular Tumor Board
5%
Circulating Tumor DNA (ctDNA)
5%
Real-world Progression-free Survival
5%
Immune Checkpoint Inhibitor Treatment
5%
Diagnostic Leukapheresis
5%
University Medical Centre
5%
